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Abstract
Background: The Obsessive Compulsive Drug Use Scale (OCDUS) measures the overall craving level within a period
from a multidimensional perspective. However, no studies have addressed the validity of the new OCDUS factor
structure, presented in 2016, in China. Additionally, there is lack of evidence on the interaction among risk factors for
relapse. We aimed to assess the psychometric properties of the scores of the Chinese version of the OCDUS in patients
with heroin dependence receiving methadone maintenance treatment (MMT). Further, we aimed to assess the
correlations of the OCDUS scores with withdrawal symptoms, depression, anxiety, and nicotine dependence.
Methods: We enrolled 113 adults (age 32–64 years) and administered them with the OCDUS, Subjective Opioid
Withdrawal Scale (SOWS), Beck Depression Inventory-II (BDI-II), State-Trait Anxiety Inventory (STAI), and Fagerstrom Test
for Nicotine Dependence (FTND).
Results: Exploratory factor analysis identified a 3-dimensional component that included “Frequency of craving,”
“Inference of heroin,” and “Control of heroin.” These factors showed acceptable internal consistency, adequate item-
total correlations, and significant item-subscale correlations. There was no correlation between the OCUDS scores and
age, education, duration of receiving MMT, and MMT dosages. However, there was a significant correlation between
the OCDUS total scores and the SOWS, STAI, BDI-II, and FTND scores. The scores of all the subscales were associated
with the SOWS scores; further, the scores of the first two subscales were associated with BDI-II scores while only the
scores of the first subscale were associated with the FTND scores.
Conclusions: Our findings support the reliability and structure validity of the OCDUS scores. Heroin craving, withdrawal
symptoms, negative emotions, and nicotine dependence, which are considered as risk factors for heroin relapse, might
interact with each other. There is a need for further studies on the underlying mechanism of these clinical phenomena.
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Background
Drug addiction is a chronic relapsing disorder that is char-
acterized by compulsions to seek and use drugs despite
significant drug-related problems [1]. Craving is an im-
portant addiction feature and has been included as a diag-
nostic criterion for substance use disorders in the DSM-5
[2]. Generally, it is defined as a subjective experience of
wanting to use a drug and is a motivational driver in ad-
dictive processes [3]. Clinical studies have used craving as
an outcome measure, while mechanism studies have used
it as the direct intervention, indicating its critical role in
basic and clinical researches. The most common tool for
assessing craving is the single-item visual analog scale
(VAS), which generally assesses the craving intensity.
However, it cannot assess the various craving dimensions,
such as frequency or duration of craving occurrences.
Therefore, a comprehensive measurement of craving is
preferred for clinical and research purposes.
The Obsessive Compulsive Drug Use Scale (OCDUS)
was developed by Flanken et al. (2002) to measure the
overall craving level for heroin within a period from a
multidimensional perspective and consisted of 13 items. It
was adapted from the Obsessive Compulsive Drinking
Scale (OCDS) composed of 14 items, which was modified
to allow assessment of craving for other substances such
as tobacco, cocaine, and cannabis [4–11]. Flanken et al.
(2002) combined two items referring to the interference of
consumption with working and social life from OCDS into
one item in the OCDUS. The OCDUS can capture the
obsessive-compulsive characteristics of drug addiction and
is frequently used in western countries. Yang et al. (2016)
validated the OCDUS among male heroin addicts in
China and presented a different factor structure of the
OCDUS from that of the original report by Flanken et al.
(2002). However, there are no studies on the validity of
the new OCDUS structure in China. Moreover, there are
no studies on the relationships among craving, negative
affect, and withdrawal, which are central in the formation
and maintenance of addiction [2].
We aimed to evaluate the psychometric properties of
the OCDUS in people with heroin dependence receiving
methadone maintenance treatment (MMT). Further, we
aimed to examine the associations of craving with with-
drawal symptoms, depression, anxiety, and nicotine de-
pendence. We hypothesized that people with a high
heroin craving level have severe withdrawal symptoms,
increased depression and anxiety, and a high nicotine
dependence degree.
Methods
Participants
A total of 113 participants completed the questionnaires.
Table 1 presents the participants’ characteristics. The
average age and educational years of the participants
were 49.9 (standard deviation [SD] = 8.15) and 10.3
(SD = 1.92), respectively, while 72.6% of the participants
were men. A majority (n = 58, 51.3%) of the participants
were married, 27.4% were divorced, and the remaining
were single. Further, majority of them had a smoking
habit (n = 110, 97.3%). Regarding the history of metha-
done use, the average duration of MMT was 90months
(SD = 51.4) while the mean dosage was 44.7 mg each
time (SD = 28.9). Further, 82.3% of the participants had
attempted to reduce their MMT dosage with 64.6% of
them succeeding.
Measures
OCDUS
The OCDUS is a self-reported scale that measures the level
of craving for drugs during the past weeks. The scale used
in this study was validated in Chinese heroin-dependent pa-
tients enrolled from detoxification centers [12]. It consists
of 13 items with the score of each item ranging from 1 to 5;
further, items 6 and 13 are reverse-scored. A higher total
score indicates a higher craving level.
Subjective opiate withdrawal scale (SOWS)
The SOWS is a self-reported 16-item scale that assesses
the presence and intensity of the opiate withdrawal ex-
perience [13]. Each item is rated on a 5-point Likert
scale ranging from 0 (not at all) to 4 (extremely). A
higher score indicates more severe withdrawal symp-
toms. The SOWS was used to measure the severity of
withdrawal symptoms of the MMT patients before in-
take of their daily methadone dose.
Table 1 Demographic characteristics of the participants
N (%)
Gender
Female 31 (27.4%)
Male 82 (72.6%)
Marriage Status
Single 24 (21.3%)
Married 58 (51.3%)
Divorced 31 (27.4%)
Smoking
Yes 110 (97.3%)
No 3 (2.7%)
Attempt to reduce MMT dose
Yes 93(82.3%)
No 13(11.5%)
Unknown 7(6.2%)
Successful attempt to reduce MMT dose
Yes 73(64.6%)
No 20(17.7%)
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Fagerstrom test for nicotine dependence (FTND)
The FTND is a 6-item scale for measuring nicotine de-
pendence [14, 15]. The total score of the scale ranges
from 0 to 10, with a higher score indicating stronger
dependence.
Beck depression inventory-II (BDI-II)
The BDI-II is a self-administrated 21-item scale for
assessing the presence of depression [16]. The score of
each item ranges from 0(absent) to 3(severe), with a
higher score indicating a more severe depression
severity.
State-trait anxiety inventory (STAI)
The STAI consists of two 20-item self-reported subscales,
namely, the STAI State (STAI-S) and STAI Trait (STAI-T)
[17]. The STAI-S assesses the transient momentary emo-
tional status, while the STAI-T assesses the general reaction
in stressful situations. Each item is rated on a 4-point Likert
scale that ranges from 1 (not at all) to 4 (very much so) for
the STAI-S and 1 (almost never) to 4 (almost always) for
the STAI-T. The score range for each subscale is 20–80,
with a higher score indicating a greater degree of anxiety.
Procedure
The study was approved by the Ruijin Hospital Ethics
Committee of Shanghai Jiao Tong University School of
Medicine. All procedures were performed in accordance
with the ethical standards of the responsible committee
on human experimentation (institutional and national)
and the Helsinki Declaration of 1975, as revised in 2008.
We enrolled participants from 3 MMT clinics in Shang-
hai. The inclusion criteria were as follows: (1) sufficient
reading proficiency to understand and complete the
questionnaires; (2) having received MMT for at least 1
month; (3) ability to provide written consent.
All the enrolled participants provided written informed
consent. Subsequently, an experimenter instructed the
participants to complete the self-reported scales in a quiet
room. The experimenter checked the completed scales for
blank entries for each item.
Data analysis
We conducted a descriptive analysis to examine the
demographic characteristics and the scales’ scores. We
used the Kolmogorov-Smirnov one-sample test to assess
whether the scales’ scores were normally distributed. We
conducted exploratory principal components analysis
with varimax rotation to determine the factor structure
of the OCDUS. We conducted confirmatory factor ana-
lysis (CFA) to investigate the model fitness based on the
exploratory factor analysis (EFA) findings. We used the
maximum likelihood chi-square statistic, the compara-
tive fit index (CFI), and the root mean square error of
approximation (RMSEA) to assess the goodness-of-fit of
the model. A χ2/df between 1.0 and 3.0 was considered
acceptable. Further, an RMSEA of 0 to 0.05 and 0.05 to
0.08 indicated a good and acceptable fit, respectively.
We considered a CFI of > 0.95 a good fit. We removed
items with a standardized regression weight of < 0.5.
Pearson’s correlation coefficients were used to examine
the item-subscale and item-total correlations of the
OCDUS. We computed Cronbach’s α to assess the in-
ternal consistency of the OCDUS. We analyzed the Pear-
son’s correlations between the OCDUS and the SOWS,
BDI-II, STAI, and FTND. The association between the
OCDUS score and the previous attempt to decrease
methadone dosage was tested by the comparison of
mean scores of the OCDUS with a T test. We conducted
statistical analyses using SPSS 18.0 with statistical sig-
nificance set at a two-tailed value of p < 0.05.
Results
EFA of the OCDUS
Kaiser-Meyer-Olkin (KMO) and Bartlett’s tests indicated
that the data were suitable for factor analysis (KMO =
0.851, p < .000). We conducted principal component
analysis to determine the factor structure of the 13-item
OCDUS. The first three eigenvalues were 5.66, 2.23, and
1.21. This three-factor model accounted for 69.26% of
the OCDUS-item variance. Table 2 presents the descrip-
tive statistics for each OCDUS item, as well as the com-
munalities and factor loadings for the three-factor
model. All items had salient (≥ 0.40) loadings on the five
factors (range from 0.59 to 0.86). The three-factor model
was similar to the factor model reported by Yang et al.
(2016). We measured the first factor using items 1, 2, 7,
8, 10, and 12; the second factor using items 3, 4, 5, and
9; and the third factor using items 6, 11, and 13.
CFA of the OCDUS
The CFA results indicated that the fit indices of the
EFA-derived three-factor model were unacceptable for
the OCDUS (χ2 = 167.36, df = 62, p < .000, RMSEA =
0.123, CFI = 0.872). The standardized regression weights
of items 5 and 11 were all < 0.5; specifically, 0.427 and −
0.482, respectively. The standardized regression weights
of the other items ranged from 0.579 to 0.936. We de-
leted items 5 and 11 due to their unacceptable standard-
ized regression weights. Further, we deleted item 10
since it evaluated aspects different from those of other
items of the first factor. Therefore, the final first factor
consisted of items 1, 2, 7, 8, and 12; the second factor
consisted of items 3, 4, and 9; and the third factor in-
cluded items 6 and 13. Moreover, the CFA results sup-
ported the final three-factor model (χ2 = 39.29, df = 32,
p < .000, RMSEA = 0.045, CFI = 0.989). The factor load-
ings on the three factors ranged from 0.54 to 0.93
Gong et al. BMC Psychiatry          (2020) 20:465 Page 3 of 7
(Table 3). Based on the study by Yang et al., the three
factors were named as “Frequency of Craving (FR),”
Interference of Heroin (IH),” and “Control of Heroin
(CH).” In the further analysis, items 5, 10, and 11 were
not included.
Reliability of the OCDUS
The internal consistency of the OCDUS was acceptable
(α = 0.87) with Cronbach’s α of 0.90, 0.87, and 0.67 for FR,
IH, CH, respectively. The Kolmogorov-Smirnov test re-
vealed no significant difference of the distribution of the
10-item OCDUS scores from a normal distribution (z
[113] = 1.21, p = 0.11). The 10-item OCDUS showed ad-
equate item-total correlations (mean [M] = 0.70, range =
0.44–0.80, Table 3), and significant item-subscale correla-
tions (M = 0.87, range = 0.84–0.92). There were significant
correlations of the 10-item OCDUS score with the sub-
scales scores; further, there were significant correlations
between the subscale scores (Table 4).
Correlations among the OCDUS, demographic variables,
and other measures
Table 4 presents the descriptive statistics and the corre-
lations among the OCDUS, demographic variables, and
other measures. There was no significant correlation of
the OCDUS scores with age (r = − 0.05, p = 0.63), educa-
tional years (r = − 0.13, p = 0.17), duration of receiving
MMT (r = − 0.02, p = 0.83), and current methadone dos-
ages (r = − 0.01, p = 0.93). There was no difference in the
OCDUS total scores between patients who wanted to re-
duce their methadone dosage and those who did not
want to reduce their methadone dosage (t = − 1.69, p =
0.09). There was a significant correlation of the SOWS
scores with the OCDUS total scores and the three subscales
scores (r = 0.31–0.61, p < 0.001). The FTND scores were
significantly correlated with the OCDUS and FR scores
(r = 0.31, 0.35, p < 0.001) but not with the IH (r = 0.18, p =
0.05) and CH (r = 0.17, p = 0.07) scores. There was a signifi-
cant correlation of the BDI-II, STAI-S, and STAI-T scores
with the OCDUS, FR, and IH scores (r = 0.40–0.52, p <
0.001). The CH scores were not significantly correlated
with the BDI-II scores (r = 0.08, p = 0.42); however, they
were moderately correlated with the STAI-S (r = 0.30, p =
0.001) and STAI-T (r = 0.21, p = 0.03) scores.
Discussion
We aimed to examine the psychometric properties of
the OCDUS and its associations with withdrawal, emo-
tions, and nicotine dependence. We found that the scale
had good structure validity with the deletion of items 5,
10, and 11; finally, we included 10 items with three sub-
scales, namely, FR, IH, and CH. The 10-item scale
showed acceptable internal consistency, adequate item-
total correlations, and significant item-subscale correla-
tions. There were significant positive correlations of the
OCDUS total scores with the SOWS, BDI, STAI-S,
STAI-T, and FTND scores. Moreover, there was an ob-
vious correlation of the SOWS, STAI-S, and STAI-T
scores with the scores of the three subscales. Further-
more, the BDI-II scores were correlated with the scores
of the FR and IH subscales; however, the FTND scores
were only correlated with the FR subscale scores.
Previous findings on the OCDUS components were in-
consistent. Flanker et al. (2002) conducted an explora-
tory factor analysis of 102 inpatients and obtained three
Table 2 The Obsessive-Compulsive Drug Use Scale (OCDUS):
Means (M), standard deviations (SD), factor loadings,
communalities (h2), and Cronbach’s α for the three-factor model
Factor loadings Cronbach’s
α(item
deletion)
The
Chinese
OCDUS
Item M SD 1 2 3 h2
8 1.74 1.14 0.85 0.15 0.14 0.76 0.869 1
12 1.53 0.96 0.84 0.11 0.08 0.73 0.875 1
2 2.01 1.00 0.83 0.25 0.07 0.76 0.867 1
7 1.96 1.03 0.82 0.24 0.06 0.74 0.869 1
10 2.29 1.31 0.70 0.26 −0.03 0.56 0.900 2
1 1.90 1.13 0.67 0.28 0.08 0.54 0.891 1
4 2.40 1.29 0.36 0.86 0.01 0.87 0.655 2
3 2.15 1.22 0.33 0.86 0.07 0.85 0.672 2
9 2.36 1.30 0.46 0.60 0.00 0.58 0.783 R
5 2.98 1.37 0.00 0.59 −0.56 0.66 0.866 2
13 2.58 1.39 0.12 0.12 0.85 0.75 0.391 3
11 2.64 1.45 0.12 0.27 −0.75 0.66 0.669 2
6 3.46 1.40 0.29 0.22 0.65 0.56 0.618 3
R: removed by Yang et al. 2016. The last column indicates the allocation of
items among factors based on Yang et al. 2016
Table 3 The standardized factor loadings of each item on the
corresponding factor and the item-total and item-subscale
correlation of the OCDUS
Item Loading Item-totalcorrelation Item-subscalecorrelation
Frequency of craving (FR)
1 0.71 0.70 0.79
2 0.90 0.80 0.90
7 0.81 0.78 0.84
8 0.83 0.78 0.87
12 0.80 0.74 0.85
Inference of heroin (IH)
3 0.91 0.74 0.92
4 0.93 0.75 0.92
9 0.66 0.68 0.83
Control of heroin (CH)
6 0.93 0.57 0.87
13 0.54 0.44 0.86
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factors, namely, “heroin thoughts and interference,” “de-
sire and control,” and “resistance to thoughts and
intention.” Finally, they obtained a 12-item scale with
deletion of item 10 and modified it to measure cocaine
craving in Dutch individuals and acquired a similar fac-
tor structure in 101 cocaine-dependent inpatients [8].
Vorspan et al. (2012) tested 116 French-speaking cocaine
users and revealed a three-factor structure scale, which
was similar to the three factors of the original OCDS
(Roberts et al. 1999). However, another study conducted
in the United States supported the two-factor structure;
it comprised of “obsessive” and “compulsive” in 107
cocaine-dependent participants [6]. A French translation
of the OCDS also developed a two-factor structure in 74
native French-speaking alcohol-dependent patients [18].
Moreover, the sample size was larger in studies identify-
ing the three-factor structure. Further, 131 male crystal-
line heroin abusers were administered with the Persian
version of the OCDUS consisting of four components
namely, “desire and mental preoccupation with drugs,”
“the effect of desire for drug and drug-related thoughts
on the patient’s work and life,” “motivation, emotion,
and lack of control,” and “resistance to drug use” [19].
Moreover, the factor structure of the Chinese version of
the OCDUS, which was validated by Yang et al. (2012)
and differed from that of versions of other countries,
was consistent with our study’s components. Therefore,
the OCDUS components are consistent within similar
countries but differ across different countries, which
might be explained by linguistic and cultural differences.
Our study revealed that the craving level was positively
associated with withdrawal symptoms and negative emo-
tions in patients with heroin dependence receiving
MMT. These associations could indicate good criterion
validity, which is suggested by the fact that this scale
assesses different craving aspects [20]. However, Yen et al.
evaluated the Desire for Drug Questionnaire in patients with
MMT, which is a frequently used instrument for measuring
the level of instant craving for heroin, and reported that crav-
ing was not associated with withdrawal symptoms; rather, it
was related to depression [21]. This inconsistency might have
resulted from the different time periods for measuring the
craving level. This study assessed the general craving during
a certain time period; further, the scales were administered
prior to daily methadone intake. Moreover, craving, with-
drawal symptoms, anxiety, and depression might increase
the risk for relapse of heroin use. There is a need for further
studies on the underlying mechanism of these associations
to promote a better understanding of the addictive process,
maintenance, and relapse.
Notably, 97.3% of our participants were smokers, and the
craving frequency was positively associated with nicotine
dependence. Previous studies have also reported a high per-
centage of smokers among heroin users [12, 22, 23]. More-
over, there was an association of nicotine dependence with
withdrawal symptoms and anxiety. The high smoking
prevalence among patients receiving MMT might be ex-
plained by the interactive effects of addictive substances
such as methadone, heroin, and nicotine [24]. However, the
sample size in this study is not large enough for a reliable
inference. Therefore, the validity of the OCDUS and the as-
sociations between craving and nicotine dependence should
be further explored in a larger sample.
Our study has several limitations. First, we did not use
a VAS as another self-reporting tool for measuring drug
craving. Moreover, we did not determine the test-retest
reliability. Third, we did not follow up on the partici-
pants to observe the relapse frequency. Future clinical
studies should further explore the craving impacts in
large representative samples.
Table 4 The descriptive statistics of the OCDUS and other measures and the Pearson correlations between them
The OCDUS total score FR IH CH M SD Range
The OCDUS 1 21.3 8.21 10–42
FR Subscale 0.90*** 1 9.2 4.46 5–23
IH Subscale 0.82*** 0.61*** 1 6.9 3.39 3–15
CH Subscale 0.59*** 0.35*** 0.24* 1 5.2 2.46 2–10
Age 0.05 −0.01 0.01 0.16 49.9 8.15 32–64
Education Years −0.13 −0.17 −0.15 0.07 10.3 1.92 6–16
Duration of receiving MMT (months) −0.02 −0.01 − 0.02 −0.02 90.1 51.39 2–224
Current Methadone Dosage (ml) −0.01 −0.01 − 0.11 0.15 44.7 28.92 2–150
SOWS 0.61*** 0.58*** 0.49*** 0.31*** 10 11.25 0–50
FTND 0.31*** 0.35*** 0.18 0.17 4.9 2.55 0–10
BDI-II 0.44*** 0.41*** 0.47*** 0.08 14.1 10.95 0–18
STAI-S 0.52*** 0.49*** 0.40*** 0.30** 36.7 11.34 20–68
STAI-T 0.49*** 0.42*** 0.48*** 0.21* 42.2 10.96 21–71
*p < 0.05, **p < 0.01, ***p < 0.001
Gong et al. BMC Psychiatry          (2020) 20:465 Page 5 of 7
Conclusion
The Chinese version of the OCDUS demonstrated good
reliability and structural validity and can be used in fu-
ture studies. Heroin craving is associated with with-
drawal symptoms, depression, anxiety, and nicotine
dependence. Further studies are needed to explore the
underlying mechanisms of these clinical phenomena.
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